German Hospital Gives First German Patient Gene-Edited Therapy for Beta-Thalassemia

Berlin's Charité university clinic reported the first German case of a patient receiving a CRISPR-derived drug, Casgevy, for beta-thalassemia. Nineteen-year-old Mohammed, previously dependent on transfusions every three weeks, now produces functional hemoglobin and no longer requires them, according to the hospital. The medication, approved in the EU since 2024 for sickle-cell disease and beta-thalassemia in patients aged twelve and up, works by editing the patient's bone-marrow stem cells and re-infusing them after a year-long protocol.

Nobel Prize winners Emmanuelle Charpentier and Jennifer Doudna invented the CRISPR system, and Charpentier personally met the patient. The procedure includes chemotherapy to clear marrow space, which carries risks such as mucosal inflammation, liver damage, and potential infertility, and patients must be monitored for 15 years. German health insurers cover the cost after a special application, but experts warn the complex, resource-intensive approach may limit scalability.